Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1815442 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $105.25Day −0.86%Mkt cap $8.7B1Y +140.8%Off 52W high −19.1%Vol (1Y) 65.7%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest12.0% of sh out |
| Days to cover14.7d |
| 13F net flow (QoQ)+8.63% |
| Top-10 13F concentration63.9% |
| Next report (est.)2026-07-30 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$51.5M |
| Earnings (TTM)-$315.0M |
| ROE−25.8% |
| Net margin−794.0% |
| ROIC−28.5% |
| Sales growth 3Y−5.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+35.3% |
| 1Y+140.8% |
| 3Y+381.0% |
| 5Y+83.4% |
| Since incept. (ann.)+13.8% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)65.7% |
| Ann. volatility (3Y)71.6% |
| Sharpe (1Y)1.65 |
| Sharpe (3Y)1.08 |
| Max drawdown (1Y)−27.7% |
| Max drawdown (3Y)−59.8% |
| Beta (3Y vs SPY)2.55 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 11.7M | $974M | — | +31.0% |
| BAKER BROS. ADVISORS LP | 8.7M | $721M | — | +0.0% |
| Avoro Capital Advisors LLC | 7.5M | $623M | — | +0.0% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.1M | $505M | — | −1.6% |
| BVF INC/IL | 5.5M | $458M | — | +0.0% |
| T. Rowe Price Investment Management, Inc. | 5.5M | $455M | — | +652.2% |
| BlackRock, Inc. | 5.1M | $422M | — | +1.1% |
| Atlas Venture Life Science Advisors, LLC | 4.6M | $381M | — | −1.8% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (96,291,482) exceed the latest reported shares-outstanding count (82,257,588) by more than securities-lending double counting can explain (FINRA short interest 9,687,598 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-30 | −$0.71 | — | $34.4M | +55.5% |
| 2025-12-31 | 2026-02-26 | — | — | $2.9M | −61.2% |
| 2025-09-30 | 2025-11-04 | −$0.94 | — | $2.8M | −26.1% |
| 2025-06-30 | 2025-08-11 | −$0.95 | — | $11.5M | −55.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-07-30 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
